RCC Risk & Follow-Up Planner
Estimate post-nephrectomy risk using the 2018 Leibovich model variables, then view a risk-adapted surveillance schedule for renal cell carcinoma (RCC).
Produced by Dr. Mohit Sharma, UROWALA
Clear cell (ccRCC)
Papillary (papRCC)
Chromophobe (chrRCC)
Clear cell RCC — progression-free survival score
Papillary RCC — simplified risk grouping
Papillary RCC risk grouping uses fewer, broader pathologic strata than the clear-cell model. This tool applies a simplified stage/size/node approximation of the published groupings — confirm exact staging with the original 2018 Leibovich publication or MDCalc before clinical use.
Chromophobe RCC — risk grouping
Suggested post-nephrectomy surveillance schedule
Low risk
Intermediate risk
High risk
| Surveillance item | Low risk | Intermediate risk | High risk |
|---|---|---|---|
| History, exam & labs (BMP, LFTs) | 6 mo, then annually to yr 5 | Every 6 mo through yr 3, then annually to yr 5 | Every 3–6 mo through yr 3, then every 6 mo to yr 5 |
| Chest imaging (CT preferred) | Annually, yrs 1–3 | Every 6 mo, yrs 1–3; annually yrs 4–5 | Every 3–6 mo, yrs 1–3; every 6 mo yrs 4–5 |
| Abdominal imaging (CT/MRI, contralateral kidney + fossa) | Baseline 3–12 mo; then only if indicated | Every 6 mo, yrs 1–3; annually yrs 4–5 | Every 3–6 mo, yrs 1–3; every 6–12 mo yrs 4–5 |
| Beyond year 5 | As clinically indicated | Consider annual imaging; late recurrences reported | Continue annual surveillance; discuss trial/adjuvant options |
Schedule reflects commonly used risk-stratified surveillance frameworks (AUA/NCCN-style) for surgically treated, non-metastatic RCC. Individualize based on comorbidities, renal function, contrast tolerance, and shared decision-making.
Produced by Dr. Mohit Sharma, UROWALA
Built to mirror the structure of the 2018 Leibovich model (Leibovich BC, Lohse CM, Cheville JC, et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma after Surgery. Eur Urol. 2018;73:772–780) for education and follow-up planning only. Point weights for clear-cell RCC reflect the published progression-free-survival variables; papillary/chromophobe groupings here are simplified approximations. This is not a validated substitute for the original publication or MDCalc, and should not replace clinical judgment, multidisciplinary input, or patient-specific decision-making.